Medical technology company Medtronic has announced plans to acquire U.S.-based Scientia Vascular in a deal valued at $550 million, aiming to expand its range of products used in stroke treatment.
Following the announcement, shares of Medtronic fell by more than 1% in early trading.
Scientia Vascular, headquartered in Salt Lake City and employing around 310 people, develops specialised guidewires and catheters designed to navigate the brain’s delicate blood vessels during neurovascular procedures.
Medtronic said these devices can be seamlessly integrated into its existing neurovascular product portfolio, strengthening its capabilities in stroke care.
Linnea Burman, Senior Vice President and President of Medtronic’s Neurovascular business, said the acquisition will help position the company with a comprehensive suite of solutions that support procedures for both hemorrhagic and acute ischemic stroke.
The company expects the transaction to close in the first half of fiscal year 2027.
Analysts at Leerink Partners said the acquisition aligns with Medtronic’s strategy to boost growth through acquisitions and reflects confidence in Scientia Vascular’s underlying technology.
Meanwhile, analysts at Evercore ISI described the move as a well-aligned tuck-in acquisition that strengthens Medtronic’s stroke treatment portfolio and complements its existing neurovascular devices.
Medtronic added that the transaction is expected to be minimally dilutive to adjusted earnings in 2027 and accretive in the years that follow. The deal could also include earn-out and milestone payments after completion, though the company did not disclose further details.
